Intragenic Mutations in Thyroid Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 2, 2008, Pages 333-362

  Sobrinho Simões, Manuel ^a,b   Máximo, Valdemar ^a   Rocha, Ana Sofia ^a   Trovisco, Vitor ^a   Castro, Patricia ^a   Preto, Ana ^a,c   Lima, Jorge ^a   Soares, Paula ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; NVPAA L881NX; NVPLBT 613AG8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAS PROTEIN; SORAFENIB; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR PAX8; WNT PROTEIN;

ANAPLASTIC CARCINOMA; ANEUPLOIDY; CITRIC ACID CYCLE; CLINICAL TRIAL; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; ONCOCYTOMA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THYROID CANCER;

ANEUPLOIDY; CARCINOMA; CITRIC ACID CYCLE; GENES, RAS; GTP-BINDING PROTEINS; HUMANS; MUTATION; OXIDATIVE PHOSPHORYLATION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, THYROTROPIN; RECOMBINANT FUSION PROTEINS; SUCCINATE DEHYDROGENASE; THYROID NEOPLASMS;

EID: 43849083525     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.02.004     Document Type: Review

References (229)

1. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 4 (2006) 292-306
2. Corvilain B., Laurent E., Lecomte M., et al. Role of the cyclic adenosine 3′,5′-monophosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab 79 1 (1994) 152-159
3. Dumont J.E., Jauniaux J.C., and Roger P.P. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci 14 2 (1989) 67-71
4. Landis C.A., Masters S.B., Spada A., et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340 6236 (1989) 692-696
5. Lyons J., Landis C.A., Harsh G., et al. Two G protein oncogenes in human endocrine tumors. Science 249 4969 (1990) 655-659
6. Suarez H.G., du Villard J.A., Caillou B., et al. Gsp mutations in human thyroid tumours. Oncogene 6 4 (1991) 677-679
7. O'Sullivan C., Barton C.M., Staddon S.L., et al. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 4 5 (1991) 345-349
8. Parma J., Duprez L., Van Sande J., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 6447 (1993) 649-651
9. Parma J., Van Sande J., Swillens S., et al. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3′,5′-monophosphate and inositol phosphate-Ca2+ cascades. Mol Endocrinol 9 6 (1995) 725-733
10. Krohn K., and Paschke R. Somatic mutations in thyroid nodular disease. Mol Genet Metab 75 3 (2002) 202-208
11. Trulzsch B., Krohn K., Wonerow P., et al. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 78 12 (2001) 684-691
12. Krohn K., Führer D., Holzapfel H.P., et al. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 83 1 (1998) 130-134
13. Tonacchera M., Vitti P., Agretti P., et al. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms. J Clin Endocrinol Metab 84 11 (1999) 4155-4158
14. Farid N.R., Shi Y., and Zou M. Molecular basis of thyroid cancer. Endocr Rev 15 2 (1994) 202-232
15. Said S., Schlumberger M., and Suarez H.G. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J Endocrinol Invest 17 5 (1994) 371-379
16. Vanvooren V., Allgeier A., Nguyen M., et al. Mutation analysis of the Epac-Rap1 signaling pathway in cold thyroid follicular adenomas. Eur J Endocrinol 144 6 (2001) 605-610
17. Castro P., Rebocho A.P., Soares R.J., et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91 1 (2006) 213-220
18. Motoi N., Sakamoto A., Yamochi T., et al. Role of Ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 196 1 (2000) 1-7
19. Esapa C.T., Johnson S.J., Kendall-Taylor P., et al. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50 4 (1999) 529-535
20. Cetani F., Tonacchera M., Pinchera A., et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. J Endocrinol Invest 22 4 (1999) 273-278
21. Spambalg D., Sharifi N., Elisei R., et al. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 81 11 (1996) 3898-3901
22. Ringel M.D., Saji M., Schwindinger W.F., et al. Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia. J Clin Endocrinol Metab 83 2 (1998) 554-559
23. Niepomniszcze H., Suarez H., Pitoia F., et al. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid 16 5 (2006) 497-503
24. Dremier S., Coppee F., Delange F., et al. Clinical Review 84: Thyroid autonomy: mechanism and clinical effects. J Clin Endocrinol Metab 81 12 (1996) 4187-4193
25. Gozu H., Avsar M., Bircan R., et al. Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma?. Thyroid 14 11 (2004) 975-980
26. Camacho P., Gordon D., Chiefari E., et al. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. Thyroid 10 11 (2000) 1009-1012
27. Russo D., Wong M.G., Costante G., et al. A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9 1 (1999) 13-17
28. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 17 (1989) 4682-4689
29. Peyssonnaux C., and Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93 1-2 (2001) 53-62
30. Vasko V., Ferrand M., Di Cristofaro J., et al. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88 6 (2003) 2745-2752
31. Lazzereschi D., Mincione G., Coppa A., et al. Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res 16 3 (1997) 325-332
32. Sugg S.L., Ezzat S., Zheng L., et al. Oncogene profile of papillary thyroid carcinoma. Surgery 125 1 (1999) 46-52
33. Nikiforova M.N., Lynch R.A., Biddinger P.W., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88 5 (2003) 2318-2326
34. Zhu Z., Gandhi M., Nikiforova M.N., et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120 1 (2003) 71-77
35. Di Cristofaro J., Marcy M., Vasko V., et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 37 7 (2006) 824-830
36. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30 2 (2006) 216-222
37. Giaretti W., Molinu S., Ceccarelli J., et al. Chromosomal instability, aneuploidy, and gene mutations in human sporadic colorectal adenomas. Cell Oncol 26 5-6 (2004) 301-305
38. Giaretti W., Pujic N., Rapallo A., et al. K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology 108 4 (1995) 1040-1047
39. Giaretti W., Rapallo A., Geido E., et al. Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation. Am J Pathol 153 4 (1998) 1201-1209
40. Fagin J.A. Minireview: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16 5 (2002) 903-911
41. Johannessen J.V., Sobrinho-Simões M., Lindmo T., et al. The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. Am J Clin Pathol 77 1 (1982) 20-25
42. Belge G., Thode B., Rippe V., et al. A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors. Hum Genet 94 2 (1994) 198-202
43. Hemmer S., Wasenius V.M., Knuutila S., et al. Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization. Br J Cancer 78 8 (1998) 1012-1017
44. Barril N., Carvalho-Sales A.B., and Tajara E.H. Interphase cytogenetic analysis of normal tissue of thyroid gland by fluorescence in situ hybridization. Cancer Genet Cytogenet 114 2 (1999) 162-164
45. Castro P., Sansonetty F., Soares P., et al. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Arch 438 4 (2001) 336-342
46. Cusick E.L., Ewen S.W., Krukowski Z.H., et al. DNA aneuploidy in follicular thyroid neoplasia. Br J Surg 78 1 (1991) 94-96
47. Schelfhout L.J., Cornelisse C.J., Goslings B.M., et al. Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 45 1 (1990) 16-20
48. Stern Y., Segal K., Medalia O., et al. DNA ploidy in papillary carcinoma of the thyroid gland in children and adolescents. Int J Pediatr Otorhinolaryngol 46 1-2 (1998) 67-70
49. Hostetter A.L., Hrafnkelsson J., Wingren S.O., et al. A comparative study of DNA cytometry methods for benign and malignant thyroid tissue. Am J Clin Pathol 89 6 (1988) 760-763
50. Soares P., and Sobrinho-Simões M. Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathol Res Pract 191 4 (1995) 304-317
51. Francia G., Azzolina L., Mantovani T., et al. Heterogeneity of nuclear DNA pattern and its relationship with cell cycle activity parameters in multinodular goitre. Clin Endocrinol (Oxf) 46 6 (1997) 649-654
52. Christov K. Flow cytometric DNA measurements in human thyroid tumors. Virchows Arch B Cell Pathol Incl Mol Pathol 51 3 (1986) 255-263
53. Schurmann G., Mattfeldt T., Feichter G., et al. Stereology, flow cytometry, and immunohistochemistry of follicular neoplasms of the thyroid gland. Hum Pathol 22 2 (1991) 179-184
54. Castro P., Eknaes M., Teixeira M.R., et al. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 206 3 (2005) 305-311
55. Joensuu H., and Klemi P.J. DNA aneuploidy in adenomas of endocrine organs. Am J Pathol 132 1 (1988) 145-151
56. Sturgis C.D., Caraway N.P., Johnston D.A., et al. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 87 3 (1999) 155-160
57. Roque L., Rodrigues R., Pinto A., et al. Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36 3 (2003) 292-302
58. Rodrigues R.F., Roque L., Rosa-Santos J., et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90 2 (2004) 492-496
59. Castro P., Roque L., Magalhaes J., et al. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol 13 3 (2005) 235-238
60. van den Berg E., Oosterhuis J.W., de Jong B., et al. Cytogenetics of thyroid follicular adenomas. Cancer Genet Cytogenet 44 2 (1990) 217-222
61. Criado B., Barros A., Suijkerbuijk R.F., et al. Detection of numerical alterations for chromosomes 7 and 12 in benign thyroid lesions by in situ hybridization. Histological implications. Am J Pathol 147 1 (1995) 136-144
62. Belge G., Roque L., Soares J., et al. Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genet Cytogenet 101 1 (1998) 42-48
63. Roque L., Nunes V.M., Ribeiro C., et al. Karyotypic characterization of papillary thyroid carcinomas. Cancer 92 10 (2001) 2529-2538
64. Sobrinho-Simões M., Preto A., Rocha A.S., et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447 5 (2005) 787-793
65. Ouyang B., Knauf J.A., Ain K., et al. Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol (Oxf) 56 3 (2002) 341-350
66. Kim D., Pemberton H., Stratford A.L., et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24 30 (2005) 4861-4866
67. Castro P., Soares P., Gusmao L., et al. H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. Oncogene 25 33 (2006) 4620-4627
68. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. [corrected]. Science 289 5483 (2000) 1357-1360
69. Marques A.R., Espadinha C., Catarino A.L., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87 8 (2002) 3947-3952
70. Cheung L., Messina M., Gill A., et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88 1 (2003) 354-357
71. Roque L., Castedo S., Clode A., et al. Deletion of 3p25-->pter in a primary follicular thyroid carcinoma and its metastasis. Genes Chromosomes Cancer 8 3 (1993) 199-203
72. Sozzi G., Miozzo M., Cariani T.C., et al. A t(2;3)(q12-13;p24-25) in follicular thyroid adenomas. Cancer Genet Cytogenet 64 1 (1992) 38-41
73. Jenkins R.B., Hay I.D., Herath J.F., et al. Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer 66 6 (1990) 1213-1220
74. Lui W.O., Kytola S., Anfalk L., et al. Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma?. Cancer Genet Cytogenet 119 2 (2000) 109-112
75. Gregory Powell J., Wang X., Allard B.L., et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 23 20 (2004) 3634-3641
76. Park J.W., Zarnegar R., Kanauchi H., et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15 3 (2005) 222-231
77. Lacroix L., Lazar V., Michiels S., et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167 1 (2005) 223-231
78. Marques A.R., Espadinha C., Frias M.J., et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91 4 (2004) 732-738
79. Sahin M., Allard B.L., Yates M., et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90 1 (2005) 463-468
80. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma. Cancer Res 63 7 (2003) 1454-1457
81. Soares P., Trovisco V., Rocha A.S., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 29 (2003) 4578-4580
82. Kim K.H., Kang D.W., Kim S.H., et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45 5 (2004) 818-821
83. Frattini M., Ferrario C., Bressan P., et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 44 (2004) 7436-7440
84. V599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas. J Clin Endocrinol Metab 89 5 (2004) 2414-2420
85. Mitsutake N., Miyagishi M., Mitsutake S., et al. BRAF mediates RET/PTC-induced MAPK activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 2 (2006) 1014-1019
86. Melillo R.M., Castellone M.D., Guarino V., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115 4 (2005) 1068-1081
87. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF Mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 11 (2003) 5399-5404
88. Trovisco V., Soares P., Preto A., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446 6 (2005) 589-595
89. Trovisco V., Vieira D.C.I., Soares P., et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202 2 (2004) 247-251
90. Fugazzola L., Mannavola D., Cirello V., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61 2 (2004) 239-243
91. Trovisco V., Soares P., Soares R., et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 36 6 (2005) 694-697
92. Oler G., Ebina K.N., Michaluart Jr. P., et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 62 4 (2005) 509-511
93. Carta C., Moretti S., Passeri L., et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns). Clin Endocrinol (Oxf) 64 1 (2006) 105-109
94. Hou P., Liu D., and Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6 3 (2007) 377-379
95. Flavin R., Smyth P., Crotty P., et al. BRAF T1799A mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15 2 (2007) 116-120
96. Schmidt J., Derr V., Heinrich M.C., et al. BRAF in papillary thyroid carcinoma of ovary (Struma Ovarii). Am J Surg Pathol 31 9 (2007) 1337-1343
97. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 6 (2004) 855-867
98. Basolo F., Giannini R., Monaco C., et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 160 1 (2002) 247-254
99. Sedliarou I., Saenko V., Lantsov D., et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 25 6 (2004) 1729-1735
100. Kim T.Y., Kim W.B., Song J.Y., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63 5 (2005) 588-593
101. Ugolini C., Giannini R., Lupi C., et al. Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid 17 5 (2007) 381-388
102. Knauf J.A., Ma X., Smith E.P., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65 10 (2005) 4238-4245
103. Liu D., Liu Z., Condouris S., et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92 6 (2007) 2264-2271
104. Fugazzola L., Puxeddu E., Avenia N., et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13 2 (2006) 455-464
105. Xu X., Quiros R.M., Gattuso P., et al. High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines. Cancer Res 63 15 (2003) 4561-4567
106. Kim T.Y., Kim W.B., Rhee Y.S., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65 3 (2006) 364-368
107. Jin L., Sebo T.J., Nakamura N., et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15 3 (2006) 136-143
108. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 12 (2005) 6373-6379
109. Namba H., Nakashima M., Hayashi T., et al. Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers. J Clin Endocrinol Metab 88 9 (2003) 4393-4397
110. Liu R.T., Chen Y.J., Chou F.F., et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63 4 (2005) 461-466
111. Chung K.W., Yang S.K., Lee G.K., et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65 5 (2006) 660-666
112. Sapio M.R., Posca D., Troncone G., et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154 2 (2006) 341-348
113. Trovisco V., Soares P., and Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 37 7 (2006) 781-786
114. Vasko V., Hu S., Wu G., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90 9 (2005) 5265-5269
115. Kim J., Giuliano A.E., Turner R.R., et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244 5 (2006) 799-804
116. Trovisco V, Couto JP, Cameselle-Teijeiro J, et al. Aquisition of BRAF gene mutations is not a requirement for nodal metastization of PTC. Clin Endocrinology, in press.
117. Cohen Y., Rosenbaum E., Clark D.P., et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10 8 (2004) 2761-2765
118. Xing M., Tufano R.P., Tufaro A.P., et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89 6 (2004) 2867-2872
119. Hayashida N., Namba H., Kumagai A., et al. A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14 11 (2004) 910-915
120. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89 10 (2004) 5175-5180
121. Domingues R., Mendonca E., Sobrinho L., et al. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 16 1 (2005) 27-31
122. Baloch Z.W., Gupta P.K., Yu G.H., et al. Follicular variant of papillary carcinoma. Cytologic and histologic correlation. Am J Clin Pathol 111 2 (1999) 216-222
123. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2 7 (2002) 543-549
124. Nikiforov Y.E., Rowland J.M., Bove K.E., et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57 9 (1997) 1690-1694
125. Nikiforova M.N., Ciampi R., Salvatore G., et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209 1 (2004) 1-6
126. Lima J., Trovisco V., Soares P., et al. BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. J Clin Endocrinol Metab 89 9 (2004) 4267-4271
127. Kumagai A., Namba H., Saenko V.A., et al. Low Frequency of BRAFT1796A Mutations in Childhood Thyroid Carcinomas. J Clin Endocrinol Metab 89 9 (2004) 4280-4284
128. Caudill C.M., Zhu Z., Ciampi R., et al. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab 90 4 (2005) 2364-2369
129. Ciampi R., Knauf J.A., Kerler R., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115 1 (2005) 94-101
130. Chong H., and Guan K.L. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 278 38 (2003) 36269-36276
131. Tran N.H., and Frost J.A. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 278 13 (2003) 11221-11226
132. Tran N.H., Wu X., and Frost J.A. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 280 16 (2005) 16244-16253
133. Penko K., Livezey J., Fenton C., et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15 4 (2005) 320-325
134. Powell N., Jeremiah S., Morishita M., et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205 5 (2005) 558-564
135. Takahashi K., Eguchi H., Arihiro K., et al. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 46 3 (2007) 242-248
136. Thompson N., and Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5 4 (2005) 350-356
137. Salvatore G., De Falco V., Salerno P., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12 5 (2006) 1623-1629
138. Preto and colleagues, submitted.
139. Ouyang B., Knauf J.A., Smith E.P., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12 6 (2006) 1785-1793
140. da Rocha Dias S., Friedlos F., Light Y., et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65 23 (2005) 10686-10691
141. Grbovic O.M., Basso A.D., Sawai A., et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103 1 (2006) 57-62
142. Máximo V., and Sobrinho-Simões M. Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437 2 (2000) 107-115
143. Cheung C.C., Ezzat S., Ramyar L., et al. Molecular basis off Hürthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85 2 (2000) 878-882
144. Máximo V., Soares P., Lima J., et al. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol 160 5 (2002) 1857-1865
145. Gasparre G., Porcelli A.M., Bonora E., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 104 21 (2007) 9001-9006
146. Máximo V., Soares P., Rocha A.S., et al. The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastruct Pathol 22 3 (1998) 271-273
147. Máximo V., and Sobrinho-Simões M. Mitochondrial DNA 'common' deletion in Hürthle cell lesions of the thyroid. J Pathol 192 4 (2000) 561-562
148. Attardi G., Yoneda M., and Chomyn A. Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochim Biophys Acta 1271 1 (1995) 241-248
149. Heddi A., Faure-Vigny H., Wallace D.C., et al. Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochim Biophys Acta 1316 3 (1996) 203-209
150. Sobrinho-Simões M., Máximo V., Castro I.V., et al. Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 13 1 (2005) 29-35
151. Yeh J.J., Lunetta K.L., Van Orsouw N.J., et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19 16 (2000) 2060-2066
152. Angell J.E., Lindner D.J., Shapiro P.S., et al. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 275 43 (2000) 33416-33426
153. Chidambaram N.V., Angell J.E., Ling W., et al. Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 20 7 (2000) 661-665
154. Lufei C., Ma J., Huang G., et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 22 6 (2003) 1325-1335
155. Fearnley I.M., Carroll J., Shannon R.J., et al. GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 276 42 (2001) 38345-38348
156. Máximo V., Botelho T., Capela J., et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. Br J Cancer 92 10 (2005) 1982-1989
157. Lima J, Máximo V, Soares P, et al. Mitochondria and oncocytomas. In: Singh KK, editor. Mitochondria and Cancer. New York: Springer, in press.
158. Eng C., Kiuru M., Fernandez M.J., et al. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3 3 (2003) 193-202
159. Gottlieb E., and Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5 11 (2005) 857-866
160. Lima J., Teixeira-Gomes J., Soares P., et al. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab 88 10 (2003) 4932-4937
161. Montani M., Schmitt A.M., Schmid S., et al. No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer 12 4 (2005) 1011-1016
162. Cascon A., Cebrian A., Pollan M., et al. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90 4 (2005) 2127-2130
163. Abu-Amero K.K., Alzahrani A.S., Zou M., et al. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. Oncogene 25 5 (2006) 677-684
164. Donghi R., Longoni A., Pilotti S., et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91 4 (1993) 1753-1760
165. Fagin J.A., Matsuo K., Karmakar A., et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91 1 (1993) 179-184
166. Wright P.A., Lemoine N.R., Goretzki P.E., et al. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6 9 (1991) 1693-1697
167. Ito T., Seyama T., Mizuno T., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52 5 (1992) 1369-1371
168. Park K.Y., Koh J.M., Kim Y.I., et al. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf) 49 3 (1998) 317-323
169. Zou M., Shi Y., and Farid N.R. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77 4 (1993) 1054-1058
170. Soares P., Cameselle-Teijeiro J., and Sobrinho-Simões M. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 24 3 (1994) 205-210
171. Saltman B., Singh B., Hedvat C.V., et al. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140 6 (2006) 899-905 [discussion: 905-6]
172. Arends J.W. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 190 4 (2000) 412-416
173. Ito T., Seyama T., Mizuno T., et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 84 5 (1993) 526-531
174. Quiros R.M., Ding H.G., Gattuso P., et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103 11 (2005) 2261-2268
175. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res 47 4-6 (1997) 145-157
176. Wynford-Thomas D., and Blaydes J. The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis 19 1 (1998) 29-36
177. Miura D., Wada N., Chin K., et al. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid 13 3 (2003) 283-290
178. Rodrigues R.F., Roque L., Krug T., et al. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer 96 8 (2007) 1237-1245
179. Wreesmann V.B., Ghossein R.A., Patel S.G., et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161 5 (2002) 1549-1556
180. Farid P., Gomb S.Z., Peter I., et al. Bcl2, p53 and bax in thyroid tumors and their relation to apoptosis. Neoplasma 48 4 (2001) 299-301
181. Hermann S., Sturm I., Mrozek A., et al. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. Int J Cancer 92 6 (2001) 805-811
182. Moore D., Ohene-Fianko D., Garcia B., et al. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology 32 1 (1998) 35-42
183. Garcia-Rostan G., Tallini G., Herrero A., et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59 8 (1999) 1811-1815
184. Tung W.S., Shevlin D.W., Bartsch D., et al. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog 15 1 (1996) 5-10
185. Basolo F., Pisaturo F., Pollina L.E., et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10 1 (2000) 19-23
186. Manenti G., Pilotti S., Re F.C., et al. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A 7 (1994) 987-993
187. Fukushima T., Suzuki S., Mashiko M., et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 41 (2003) 6455-6457
188. Garcia-Rostan G., Zhao H., Camp R.L., et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21 17 (2003) 3226-3235
189. Wang Y., Hou P., Yu H., et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92 6 (2007) 2387-2390
190. Hou P., Liu D., Shan Y., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13 4 (2007) 1161-1170
191. Garcia-Rostan G., Camp R.L., Herrero A., et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158 3 (2001) 987-996
192. Kim W.B., Lewis C.J., McCall K.D., et al. Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol 193 1 (2007) 93-106
193. Rocha A.S., Soares P., Fonseca E., et al. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42 6 (2003) 580-587
194. Kurihara T., Ikeda S., Ishizaki Y., et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 14 12 (2004) 1020-1029
195. Sobrinho-Simões M., Sambade C., Fonseca E., et al. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol 10 2 (2002) 123-131
196. Cameselle-Teijeiro J., Ruiz-Ponte C., Loidi L., et al. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. Am J Clin Pathol 115 4 (2001) 486-493
197. Cameselle-Teijeiro J., and Chan J.K. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma?. Mod Pathol 12 4 (1999) 400-411
198. Soares P., Trovisco V., Rocha A.S., et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444 6 (2004) 572-576
199. In: DeLellis R.A., Heitz P.U., and Eng C. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine glands (2004), IARC Press, Lyon
200. Ashfaq R., Vuitch F., Delgado R., et al. Papillary and follicular thyroid carcinomas with an insular component. Cancer 73 2 (1994) 416-423
201. Carcangiu M.L., Zampi G., and Rosai J. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am J Surg Pathol 8 9 (1984) 655-668
202. Papotti M., Botto Micca F., Favero A., et al. Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol 17 3 (1993) 291-301
203. Takano T., Ito Y., Hirokawa M., et al. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96 10 (2007) 1549-1553
204. Tallini G., Santoro M., Helie M., et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4 2 (1998) 287-294
205. Wu G., Mambo E., Guo Z., et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90 8 (2005) 4688-4693
206. Garcia-Rostan G., Costa A.M., Pereira-Castro I., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65 22 (2005) 10199-10207
207. Liu D., Mambo E., Ladenson P.W., et al. Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90 9 (2005) 5509
208. Santoro M., Papotti M., Chiappetta G., et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87 1 (2002) 370-379
209. Dwight T., Thoppe S.R., Foukakis T., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88 9 (2003) 4440-4445
210. Nakashima M., Takamura N., Namba H., et al. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol 38 4 (2007) 621-628
211. Takeshita A., Nagayama Y., Yokoyama N., et al. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab 80 9 (1995) 2607-2611
212. Tanaka K., Nagayama Y., Takeshita A., et al. Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan. Thyroid 6 3 (1996) 195-199
213. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas-a note of caution. J Clin Endocrinol Metab 81 8 (1996) 2783-2785
214. Parma J., Duprez L., Van Sande J., et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82 8 (1997) 2695-2701
215. Vassart G. New pathophysiological mechanisms for hyperthyroidism. Horm Res 48 Suppl 4 (1997) 47-50
216. Führer D., Holzapfel H.P., Wonerow P., et al. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 82 11 (1997) 3885-3891
217. Führer D., Kubisch C., Scheibler U., et al. The extracellular thyrotropin receptor domain is not a major candidate for mutations in toxic thyroid nodules. Thyroid 8 11 (1998) 997-1001
218. Tonacchera M., Agretti P., Chiovato L., et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 85 6 (2000) 2270-2274
219. Krohn K., Reske A., Ackermann F., et al. Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol (Oxf) 55 2 (2001) 241-248
220. Russo D., Arturi F., Wicker R., et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 80 4 (1995) 1347-1351
221. Russo D., Tumino S., Arturi F., et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab 82 3 (1997) 735-738
222. Bourasseau I., Savagner F., Rodien P., et al. No evidence of thyrotropin receptor and Gs(alpha) gene mutation in high iodine uptake thyroid carcinoma. Thyroid 10 9 (2000) 761-765
223. Führer D., Tannapfel A., Sabri O., et al. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocr Relat Cancer 10 4 (2003) 591-600
224. Dobashi Y., Sakamoto A., Sugimura H., et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17 4 (1993) 375-381
225. Ho Y.S., Tseng S.C., Chin T.Y., et al. p53 gene mutation in thyroid carcinoma. Cancer Lett 103 1 (1996) 57-63
226. Takeuchi Y., Daa T., Kashima K., et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 9 4 (1999) 377-381
227. Capella G., Matias-Guiu X., Ampudia X., et al. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5 1 (1996) 45-52
228. Pilotti S., Collini P., Mariani L., et al. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol 21 12 (1997) 1466-1473
229. Fukushima T., and Takenoshita S. Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci 51 2 (2005) 67-75